Literature DB >> 10477535

Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism.

G A Figtree1, Y Lu, C M Webb, P Collins.   

Abstract

BACKGROUND: Selective estrogen receptor modulators (SERMs) have been defined as compounds that display tissue specificity with regard to estrogenic effects. They appear to share the beneficial effects of estrogen on bone and lipids but are not associated with an increased risk of breast or uterine carcinoma. Estrogen relaxes coronary arteries and has long-term protective effects on the vascular system. The effect of SERMs on the coronary vasculature is unknown. We therefore investigated the effects of the SERM raloxifene on isolated rabbit coronary arteries. METHODS AND
RESULTS: Rings of coronary artery from adult male and nonpregnant female New Zealand White rabbits were suspended in organ baths containing Krebs solution; isometric tension was then measured. Raloxifene induced coronary arterial relaxation in male and female coronary arteries by an endothelium-dependent and estrogen receptor-dependent mechanism involving nitric oxide. Raloxifene also had a direct calcium antagonistic effect on the coronary myocyte. Estrogen, however, induced only endothelium-independent coronary arterial relaxation. The endothelium-dependent component of relaxation induced by raloxifene 10(-6) mol/L resulted in almost 100% (79+/-7% versus 43+/-3%, P<0.001) more relaxation than that induced by estrogen 10(-6) mol/L.
CONCLUSIONS: These data demonstrate that raloxifene has vascular relaxing properties. The surprising finding is that the receptor-dependent effects via the endothelium are observed in coronary arteries from both male and female animals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477535     DOI: 10.1161/01.cir.100.10.1095

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

Review 1.  Selective estrogen receptor modulators.

Authors:  Henry U Bryant
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function.

Authors:  Matthias R Meyer; Eric R Prossnitz; Matthias Barton
Journal:  Vascul Pharmacol       Date:  2011-07-05       Impact factor: 5.773

3.  Equilin displays similar endothelium-independent vasodilator potential to 17β-estradiol regardless of lower potential to inhibit calcium entry.

Authors:  Fernando P Filgueira; Núbia S Lobato; Denise L Nascimento; Graziela S Ceravolo; Fernanda R C Giachini; Victor V Lima; Ana Paula Dantas; Zuleica B Fortes; R Clinton Webb; Rita C Tostes; Maria Helena C Carvalho
Journal:  Steroids       Date:  2018-11-17       Impact factor: 2.668

4.  GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure.

Authors:  Matthias R Meyer; Eric R Prossnitz; Matthias Barton
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011

5.  The effects of raloxifene hydrochloride on ocular hemodynamics and visual function.

Authors:  Brent Siesky; Alon Harris; Nisha Kheradiya; Rita Ehrlich; Carissa Klaas; Boaris Kaplan; Yara Catoira; Lynne McCranor; Carlos Rospigliosi; Mira Harris
Journal:  Int Ophthalmol       Date:  2008-04-22       Impact factor: 2.031

6.  Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors.

Authors:  Peter Collins; Lori Mosca; Mary Jane Geiger; Deborah Grady; Marcel Kornitzer; Messan G Amewou-Atisso; Mark B Effron; Sherie A Dowsett; Elizabeth Barrett-Connor; Nanette K Wenger
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

Review 7.  Non-nuclear actions of estrogen: new targets for prevention and treatment of cardiovascular disease.

Authors:  Karen J Ho; James K Liao
Journal:  Mol Interv       Date:  2002-07

8.  Therapeutic concentrations of raloxifene augment nitric oxide-dependent coronary artery dilatation in vitro.

Authors:  F P Leung; L M Yung; H S Leung; C L Au; X Yao; P M Vanhoutte; I Laher; Y Huang
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

9.  Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current.

Authors:  Reginald Liew; Mark A Stagg; Kenneth T MacLeod; Peter Collins
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

Review 10.  G-protein-coupled estrogen receptor as a new therapeutic target for treating coronary artery disease.

Authors:  Guichun Han; Richard E White
Journal:  World J Cardiol       Date:  2014-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.